

CB8 Meeting on the High Cost of Prescription Medicine

March 21st, 2023

Agenda

- The Inflation Reduction Act
- The President's Budget
- Rep. Nadler's Sponsored and Cosponsored Bills
- What You Can Do
- Q&A

Prescription Drug Provisions in the Inflation Reduction Act

- → For the first time, requires the federal government to negotiate prices for some top-selling drugs covered under Medicare
- Requires drug companies to pay rebates if prices rise faster than inflation for drugs used by Medicare beneficiaries
- → Eliminates 5% coinsurance for catastrophic coverage in Medicare Part D in 2024, adds a \$2,000 cap on Part D out-of-pocket spending in 2025, and limits annual increases in Part D premiums for 2024-2030
- → Limits monthly cost sharing for insulin products to \$35 for people with Medicare
- → Expands eligibility for Medicare Part D Low-Income Subsidy full benefits
- → Eliminates cost sharing for adult vaccines covered under Medicare Part D and improves access to adult vaccines under Medicaid and CHIP
- → Further delays implementation of the Trump Administration's drug rebate rule



Source: KFF, March 2023

Implementation Timeline of the Prescription Drug Provisions in the Inflation Reduction Act

2023

2024

2025

2026

2027

2028

2029

Requires drug companies to pay rebates if drug prices rise faster than

inflation

Eliminates 5% coinsurance for Part D catastrophic coverage

Adds \$2,000 out-of-pocket cap in Part D and other drug benefit changes

•10 Medicare Part D drugs

•15 Medicare Part D drugs

Implements negotiated prices for certain high-cost drugs:

15 Medicare
 Part B and
 Part D drugs

 20 Medicare Part B and Part D drugs

Limits insulin cost sharing to \$35/month in Part B & D

Reduces costs and improves coverage for adult vaccines in Medicare Part D, Medicaid & CHIP Expands
eligibility
for Part D
Low-Income
Subsidy full
benefits up to

150% FPL

Further delays implementation of the Trump Administration's drug rebate rule to 2032

2024-2030: Limits Medicare Part D premium growth to no more than 6% per year

Source: KFF, March 2023

The President's Budget

The Budget proposes:

- Expanding Medicare's Ability to Negotiate Drug Prices
- Expanding the IRA's requirement that drug companies pay rebates when they increase prices faster than inflation
- Strengthening the Medicaid Drug Rebate Program

The President's Budget Continued

- Extending Medicare solvency by 25 Years or more by modestly increasing the Medicare tax rate on income above \$400,000
- Capping Part D cost-sharing on certain generic drugs, such as those used to treat chronic conditions like hypertension and high cholesterol, to \$2 per prescription per month.

Rep. Nadler's Bills

Sponsored:

- Prescription Pricing for the People Act of 2019
- Preserve Access to Affordable Generics and Biosimilars Act

Cosponsored:

Medicare Negotiation and Competitive Licensing Act

What You Can Do

- Share your stories with your Representatives and Senators
- Encourage friends to reach out to their Members of Congress
- Engage with advocacy groups





Staff Contact Information

Andrew Heineman

Andrew.Heineman@mail.house.gov

Alison Cohen

Alison.Cohen@mail.house.gov

https://nadler.house.gov/